Northwire Canada EditionThursday, October 15, 2026
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Financings

Aurora Spine cuts loan rate, extends insider note

ASG · Price

Executive Summary

  • Aurora Spine Corp. has amended an existing $1.6 million insider loan, reducing the interest rate from 9% to 4.5% per annum effective January 1, 2026, and extending the maturity date from June 29, 2027, to July 11, 2029.
  • The amendment introduces a change of control acceleration clause, allows penalty-free prepayment, and maintains the subsidiary guarantee while constituting a related party transaction exempt from formal valuation and minority approval requirements.

Key Details

  • Principal Amount: $1.6 million (U.S.)
  • Accrued/Unpaid Interest: $1,249,500 (U.S.)
  • Interest Rate: Reduced from 9% to 4.5% per annum (effective Jan. 1, 2026); defaults to 12% per annum or maximum legal rate upon event of default
  • Maturity Date: Extended from June 29, 2027, to July 11, 2029
  • Change of Control: Maturity will be accelerated, making the note due and payable in full upon written request from the holder
  • Prepayment: Company may prepay principal and accrued interest in whole or in part at any time without penalty
  • Guarantee & Security: Wholly owned subsidiary Aurora Spine Inc. continues to guarantee and secure the company's obligations under the note
  • Use of Proceeds: General corporate purposes
  • Regulatory Classification: Related party transaction under Multilateral Instrument 61-101; exempt from formal valuation and minority approval requirements
  • Conditions: Subject to receipt of all necessary approvals
Read the original news release →

More from Aurora Spine Corp